Zymeworks (FRA:ZA8) Cyclically Adjusted FCF per Share: €-1.31 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZA8 Zymeworks Inc FRA:ZA8
48 GF Score
Price €20.68
GF Value €13.51
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Zymeworks Cyclically Adjusted FCF per Share?

Zymeworks FRA:ZA8 48 Cyclically Adjusted FCF per Share is €-1.31 as of Jun. 2026. GuruFocus rates FRA:ZA8 with a GF Score™ of 48/100 and a GF Value™ of €13.51 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Zymeworks's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.380. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.31 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-13), Zymeworks's current stock price is €20.68. Zymeworks's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-1.31. Zymeworks's Cyclically Adjusted Price-to-FCF of today is .


Zymeworks  (FRA:ZA8) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Zymeworks Cyclically Adjusted FCF per Share Related Terms


Zymeworks Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Zymeworks's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks Cyclically Adjusted FCF per Share Chart

Zymeworks Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.37

Zymeworks Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.40 -1.37 -1.37 -1.31

FRA:ZA8 vs MPLT, SRPT, GENB: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Zymeworks's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zymeworks's Cyclically Adjusted Price-to-FCF falls into.


FRA:ZA8
48GF Score
Zymeworks Inc FRA:ZA8
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zymeworks Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zymeworks's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.38/333.9520*333.9520
=-0.380

Current CPI (Jun. 2026) = 333.9520.

Zymeworks Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.718 241.428 -0.993
201612 -0.543 241.432 -0.751
201703 -0.646 243.801 -0.885
201706 -0.612 244.955 -0.834
201709 -0.444 246.819 -0.601
201712 1.283 246.524 1.738
201803 -0.565 249.554 -0.756
201806 0.130 251.989 0.172
201809 -0.413 252.439 -0.546
201812 1.369 251.233 1.820
201903 -0.590 254.202 -0.775
201906 -0.396 256.143 -0.516
201909 -0.442 256.759 -0.575
201912 -0.795 256.974 -1.033
202003 -0.714 258.115 -0.924
202006 -0.902 257.797 -1.168
202009 -0.312 260.280 -0.400
202012 -0.786 260.474 -1.008
202103 -0.679 264.877 -0.856
202106 -0.842 271.696 -1.035
202109 -0.911 274.310 -1.109
202112 -0.953 278.802 -1.142
202203 -0.889 287.504 -1.033
202206 -0.835 296.311 -0.941
202209 -1.167 296.808 -1.313
202212 4.619 296.797 5.197
202303 -1.170 301.836 -1.294
202306 -0.099 305.109 -0.108
202309 -0.582 307.789 -0.631
202312 0.158 306.746 0.172
202403 -0.462 312.332 -0.494
202406 -0.317 314.175 -0.337
202409 -0.081 315.301 -0.086
202412 -0.535 315.605 -0.566
202503 -0.046 319.799 -0.048
202506 0.125 322.561 0.129
202509 -0.358 324.800 -0.368
202512 -0.124 324.054 -0.128
202603 -0.532 330.213 -0.538
202606 -0.380 333.952 -0.380

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.31 mean?
Zymeworks (FRA:ZA8) has a Cyclically Adjusted FCF per Share of €-1.31 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Zymeworks and its competitors.
Is Zymeworks' Cyclically Adjusted FCF per Share too high?
Zymeworks' current Cyclically Adjusted FCF per Share is €-1.31. Overall, Zymeworks has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Cyclically Adjusted FCF per Share compare to MPLT and SRPT?
Zymeworks' Cyclically Adjusted FCF per Share of €-1.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Zymeworks and its competitors. Zymeworks's current Cyclically Adjusted FCF per Share is €-1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (FRA:ZA8) is currently considered Significantly Overvalued. The stock's GF Value™ is €13.51, compared to a current price of €20.68 — trading 53.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-1.31. Zymeworks' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Zymeworks (FRA:ZA8), the current Cyclically Adjusted FCF per Share is €-1.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zymeworks (FRA:ZA8) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of €20.68 is trading 53.1% above its estimated GF Value™ of €13.51. GuruFocus considers Zymeworks to be Significantly Overvalued.

Key valuation signals for FRA:ZA8:

  • Cyclically Adjusted FCF per Share: €-1.31
  • GF Value™: €13.51 vs. price of €20.68 (53.1% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:ZA8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zymeworks Business Description

Other Exchanges ZYME:USAZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
48GF Score

Get the complete analysis for FRA:ZA8

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.68
Price
€13.51
GF Value